PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 29, 2010New England Journal of Medicine1,831 citationsOpen Access

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

View Full Paper
AYAlice L. YuAGAndrew L. GilmanMÖM. Fevzi Özkaynak

Key Points

  • The aim is to evaluate the effectiveness of anti-GD2 antibody therapy combined with GM-CSF and interleukin-2 in treating high-risk neuroblastoma.
  • Immunotherapy involving anti-GD2 antibody ch14.18, GM-CSF, and interleukin-2.
  • Comparison with standard therapy.
  • ClinicalTrials.gov number: NCT00026312.
  • Immunotherapy was associated with significantly improved outcomes compared to standard therapy.

Abstract

Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma. (Funded by the National Institutes of Health and the Food and Drug Administration; ClinicalTrials.gov number, NCT00026312.)

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Yu et al. (2010) studied this question.

synapsesocial.com/papers/69dd6070ae7c4d5b29100f12https://doi.org/10.1056/nejmoa0911123
Ask AI
Helpful
Bookmark
Share
View Full Paper